Trio Medicines is a pharmaceutical and biotechnology company focused on developing innovative medicines to address diseases with significant unmet medical needs. Founded in 2007, the company initially aimed to bring netazepide, a gastrin/CCK 2 receptor antagonist, to clinical use. Over time, Trio has expanded its pipeline to include additional molecules such as ceclazepide, another gastrin/CCK 2 receptor antagonist, TR4, a selective β2-adrenoceptor antagonist, and TR8, a formyl peptide receptor 2 agonist. This diverse pipeline reflects Trio's commitment to advancing therapeutic options in various medical areas.

The company operates in collaboration with its parent organization, HMR Ltd, which provides essential facilities, resources, and expertise for conducting early clinical trials. Trio Medicines is actively seeking partnerships for pivotal phase 3 studies of netazepide and further investigations of ceclazepide, indicating a strategic approach to advancing its drug development efforts. Through these initiatives, Trio aims to leverage its scientific foundation and innovative research to deliver effective treatments for patients in need.

United Kingdom

Trio Medicines Ltd (Trio) is a small pharmaceutical company founded in 2005, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO.
Here, we focus on developing treatments for rare and unmet medical needs with the aim of improving the health and quality of life of patients around the world.

Here at Trio, we are currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions.  Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).

Trio Medicines

Company Details